Sulfhydryl regulation of L-selectin shedding: phenylarsine oxide promotes activation-independent L-selectin shedding from leukocytes.
The L-selectin adhesion molecule mediates leukocyte recruitment to inflammatory sites and lymphocyte trafficking through the peripheral lymph nodes. In response to leukocyte activation, L-selectin is proteolytically released from the cell surface, disabling leukocytes from the subsequent L-selectin-dependent interactions. We have found that L-selectin shedding is sensitive to sulfhydryl chemistry; it is promoted by thiol-oxidizing or -blocking reagents and inhibited by reducing reagents. Phenylarsine oxide (PAO), a trivalent arsenical that interacts with vicinal dithiols, is most potent in inducing rapid shedding of L-selectin from isolated neutrophils, eosinophils, and lymphocytes as well as from neutrophils in whole blood. PAO does not cause cell activation, nor does it interfere with integrin function or alter the expression of several other cell surface molecules at the low concentrations that induce L-selectin shedding. PAO is not required to enter the cell to induce L-selectin shedding. TAPI-2 ((N-(D,L-[2-(hydroxyaminocarbonyl)-methyl]-4-methylpentanoyl)-L-3-(tert-butyl)-alanyl-l -alanine, 2-aminoethyl amide), which has previously been shown to inhibit the activation-dependent L-selectin shedding, is also capable of inhibiting PAO-induced L-selectin shedding. We hypothesize that PAO-induced L-selectin shedding involves a regulatory molecule, such as protein disulfide isomerase (PDI), an enzyme that plays a role in the formation and rearrangement of disulfide bonds, contains PAO-binding, vicinal dithiol-active sites, and is expressed on the neutrophil surface. Cell surface expression of PDI, L-selectin shedding induced by PDI-blocking Abs and by bacitracin, a known inhibitor of PDI activity, and direct binding of PDI to PAO, provide supporting evidence for this hypothesis.
Bennett
T A
TA
Department of Pathology, Division of Cytometry, Cancer Research Facility, University of New Mexico School of Medicine, Albuquerque, NM 87131, USA.
Edwards
B S
BS
Sklar
L A
LA
Rogelj
S
S
D001152:Arsenicals / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D018821:CD18 Antigens / Q000378:metabolism / Q000502:physiology; D002449:Cell Aggregation / Q000187:drug effects / Q000276:immunology; D004112:Dimercaprol / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D019041:L-Selectin / Q000378:metabolism*; D007962:Leukocytes / Q000276:immunology / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D008214:Lymphocytes / Q000276:immunology / Q000378:metabolism; D018375:Neutrophil Activation / Q000187:drug effects / Q000276:immunology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding / Q000187:drug effects / Q000276:immunology; D012995:Solubility; D013439:Sulfhydryl Reagents / Q000494:pharmacology*
D001152:Arsenicals; D018821:CD18 Antigens; D006877:Hydroxamic Acids; D013439:Sulfhydryl Reagents; C099410:TAPI-2; D004112:Dimercaprol; C029341:oxophenylarsine; D019041:L-Selectin